Value-Based Medtech Rides The Money-Go-Round Into 2016

The wider medtech industry saw only 2% growth in 2015, and medtechs in established markets face continued low growth for the next three to five years. The medtech M&A bonanza continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers; longer term, there are signs of a change in the top global medtech rankings.

The technology-driven medical device industry: that’s so 2014. The 2016 medtech executive has other things on his/her mind, and they all come under the general job title of “value-based health care delivery chain partner.” Titles are not as simple as they once were, and while no one yet wears that precise title on his/her lapel badge (come to that, lapels are not what they once were), medtech companies in the 2010s know they are playing in a totally different arena and are part of an industry in transformation.

This has happened due to the convergence of several factors related to provider/payer cost savings, rising demand for care, a...

More from Strategy

More from Business